Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series
Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series
复制标题
DOI：
10.1097/meg.0b013e3283525a7b
复制
发表时间：
2012-07-01
影响因子：
2.1
通讯作者：
Marin-Jimenez, Ignacio
中科院分区：
文献类型：
--
作者：
Barreiro-de Acosta, Manuel;Garcia-Bosch, Orlando;Marin-Jimenez, Ignacio
英夫利昔单抗（IFX）已被用作难治性结肠袋炎的补救治疗;然而，没有使用阿达木单抗（ADA）的临床证据。本研究的目的是报告ADA的疗效与IFX.Methods治疗的难治性结肠袋炎患者的回顾性，开放标签，病例系列设计。纳入接受ADA治疗的慢性难治性结肠袋炎患者。所有患者既往均接受过IFX治疗。结果8例慢性难治性结肠袋炎患者均接受ADA治疗。8周后，13%的患者获得缓解，62%的患者显示出临床反应。在第26周，13%达到缓解，38%显示临床反应。在第52周，50%的患者避免了永久性回肠造口术，但只有25个实现remission.Conclusion ADA治疗被发现是一种替代慢性难治性结肠袋炎患者以前用IFX治疗。Eur J Gastroenterol Hepatol 24：756-758（c）2012 Wolters Kluwer Health垂直条Lippincott威廉姆斯& Wilkins。
Aim In refractory pouchitis, infliximab (IFX) has been used as rescue therapy; however, there is no clinical evidence for the use of adalimumab (ADA). The aim of this study was to report the efficacy of ADA in patients with refractory pouchitis previously treated with IFX.Methods A retrospective, open-label, case series was designed. Patients with chronic refractory pouchitis treated with ADA were included. All patients were previously treated with IFX. The short-term and mid-term efficacy of ADA was evaluated.Results Eight patients with chronic refractory pouchitis treated with ADA were included. After 8 weeks, 13% of the patients achieved remission and 62% showed a clinical response. At week 26, 13% achieved remission and 38% showed a clinical response. At week 52, 50% of the patients avoided a permanent ileostomy but only 25 achieved remission.Conclusion ADA treatment was found to be an alternative for patients with chronic refractory pouchitis previously treated with IFX. Eur J Gastroenterol Hepatol 24:756-758 (c) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.